TriangleNCT02684058 · OUTCOME
LGG Cohort: Kaplan-Meier Progression-Free Survival (PFS) as Per Investigator Assessment Using RANO Criteria
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to approx. 3 years and up to approx 4.2 years
What was measured
Time from the date of randomization to the date of first documented disease progression as per investigator assessment using RANO criteria or death due to any cause. Confidence Intervals were estimated using the Brookmeyer Crowley method. Patients who had not progressed or died or had received further anticancer therapy were censored at the date of the last adequate tumor evaluation.
Analysis population: Participants on the LGG cohort to whom study treatment had been assigned by randomization regardless of whether or not treatment was administered. According to the intent to treat principle, patients were analyzed according to the treatment they had been assigned to during the randomization procedure.
Groups in this outcome
LGG Cohort: Dabrafenib and Trametinib
Participants in the LGG cohort randomized to receive dabrafenib (orally, twice daily and dosed based on weight and age) in combination with trametinib (orally, once daily in combination with the first daily dose of dabrafenib and was dosed based on weight)
LGG Cohort: Carboplatin and Vincristine
Participants in the LGG cohort randomized to receive active comparator chemotherapy (carboplatin and vincristine). Participants received one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy. Participants were allowed to crossover to dabrafenib and trametinib after centrally confirmed and RANO-defined disease progression.
| Group | Source count |
|---|---|
| LGG Cohort: Dabrafenib and Trametinib | 73 |
| LGG Cohort: Carboplatin and Vincristine | 37 |
Reported measurements
Up to approx. 3 years
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| LGG Cohort: Dabrafenib and Trametinib | NA | Not reported | NA | NA | Not estimable (NA) due to the insufficient number of participants with events |
| LGG Cohort: Carboplatin and Vincristine | NA | Not reported | 12.6 | NA | Not estimable (NA) due to the insufficient number of participants with events |
Up to approx 4.2 years
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| LGG Cohort: Dabrafenib and Trametinib | 46.0 | Not reported | 38.6 | NA | Not estimable (NA) due to the insufficient number of participants with events |
| LGG Cohort: Carboplatin and Vincristine | 30.8 | Not reported | 7.0 | NA | Not estimable (NA) due to the insufficient number of participants with events |
Complete source fields
- classes
- categories
- measurements
- comment
- Not estimable (NA) due to the insufficient number of participants with events
- group Id
- OG000
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- comment
- Not estimable (NA) due to the insufficient number of participants with events
- group Id
- OG001
- lower Limit
- 12.6
- upper Limit
- NA
- value
- NA
- title
- Up to approx. 3 years
- categories
- measurements
- comment
- Not estimable (NA) due to the insufficient number of participants with events
- group Id
- OG000
- lower Limit
- 38.6
- upper Limit
- NA
- value
- 46.0
- comment
- Not estimable (NA) due to the insufficient number of participants with events
- group Id
- OG001
- lower Limit
- 7.0
- upper Limit
- NA
- value
- 30.8
- title
- Up to approx 4.2 years
- denoms
- counts
- group Id
- OG000
- value
- 73
- group Id
- OG001
- value
- 37
- units
- Participants
- description
- Time from the date of randomization to the date of first documented disease progression as per investigator assessment using RANO criteria or death due to any cause. Confidence Intervals were estimated using the Brookmeyer Crowley method. Patients who had not progressed or died or had received further anticancer therapy were censored at the date of the last adequate tumor evaluation.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants in the LGG cohort randomized to receive dabrafenib (orally, twice daily and dosed based on weight and age) in combination with trametinib (orally, once daily in combination with the first daily dose of dabrafenib and was dosed based on weight)
- id
- OG000
- title
- LGG Cohort: Dabrafenib and Trametinib
- description
- Participants in the LGG cohort randomized to receive active comparator chemotherapy (carboplatin and vincristine). Participants received one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy. Participants were allowed to crossover to dabrafenib and trametinib after centrally confirmed and RANO-defined disease progression.
- id
- OG001
- title
- LGG Cohort: Carboplatin and Vincristine
- param Type
- MEDIAN
- population Description
- Participants on the LGG cohort to whom study treatment had been assigned by randomization regardless of whether or not treatment was administered. According to the intent to treat principle, patients were analyzed according to the treatment they had been assigned to during the randomization procedure.
- reporting Status
- POSTED
- time Frame
- Up to approx. 3 years and up to approx 4.2 years
- title
- LGG Cohort: Kaplan-Meier Progression-Free Survival (PFS) as Per Investigator Assessment Using RANO Criteria
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice